Guardant Health and Adicon announce strategic partnership to offer comprehensive genomic profiling tests to accelerate development of new cancer therapies in China

Collaboration will provide biopharmaceutical companies access to Guardant Health's broad portfolio of cancer tests to help advance drug development programs and their clinical trials

SINGAPORE, July 6, 2022 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Adicon Holdings Limited, a leading independent clinical laboratory company based in China, today announced a strategic partnership to offer Guardant Health's comprehensive genomic profiling (CGP) tests to biopharmaceutical companies conducting clinical trials in China.

As part of the relationship, Guardant Health will license to Adicon its industry-leading liquid biopsy technology, including the Guardant360^® and GuardantOMNI^TM tests, and the Guardant360 TissueNext^TM tissue-based biopsy for patients with any solid cancerous tumor. These tests help researchers identify patients whose cancer has the right molecular profile for their clinical programs, streamlining patient screening and clinical trial enrollment, and also providing insights into patient response, tumor evolution and resistance. In addition, Guardant Reveal^TM, the first blood-only test that detects residual disease and monitors for cancer recurrence, will be offered to biopharmaceutical companies for early-stage cancer research and development.

"Our partnership with Adicon marks another important milestone for Guardant Health, and we are excited to bring our comprehensive genomic profiling tests and services to researchers in China," said Helmy Eltoukhy, Guardant Health co-CEO. "With Adicon's extensive expertise in clinical laboratory services, we believe they are the ideal partner to help biopharmaceutical companies bring the next generation of cancer therapies to patients in the region."  

In 2020, over 4.5 million people in China were diagnosed with cancer, and there were over 3 million cancer-related deaths, making cancer the leading cause of death in the country. The most prevalent cancer types among men and women in China include lung (18%), colorectal (12%) and stomach (11%).^{[1], [2]}

"We are very excited to be partnering with Guardant Health, a global leader in CGP testing, to bring a world-class testing platform to China. It transforms Adicon's ability to serve biopharmaceutical customers and beyond. We are very committed to working with Guardant, our customers, as well as other stakeholders to bring the best novel therapies to Chinese patients," said Ling Yang, chairwoman of Adicon Holdings Limited. 

"Increasing incidence rates have made cancer a high priority in China and have led to a rising number of clinical trials in the region," said Lawrence Wang, Chief Financial Officer of Adicon Holdings Limited. "With our CAP accredited laboratory in Shanghai, we are delighted to partner with Guardant Health to make its cancer tests available for biopharmaceutical partners in China."

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening. For more information, visit guardanthealth.com and follow the company on LinkedIn and Twitter.

Guardant Health Forward-Looking Statement

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2021 and in its other reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.

_References

1. _{International Agency for Research on Cancer. https://gco.iarc.fr/today/data/factsheets/populations/160-china-fact-sheets.pdf. Accessed online May 30, 2022.}
2. _{Xia, C, Dong X. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chinese Medical Journal. 2022 March 5; 135(5):584:590. doi: 10.1097/CM9.0000000000002108.}

Guardant Health Contacts

Investor Contact:
Alex Kleban
[email protected]
+1 657-254-5417

Media Contact:
Prakash Raja
[email protected] 
+65 90051001

Logo - https://mma.prnewswire.com/media/1429866/Guardant_Logo.jpg